Financial Performance - The company's revenue for Q3 2022 was ¥951,832,790.96, representing a decrease of 19.04% compared to the same period last year[5] - Net profit attributable to shareholders was ¥16,375,135.40, down 90.10% year-on-year, while the net profit excluding non-recurring gains and losses was ¥10,653,063.48, a decrease of 61.34%[5] - The company's basic earnings per share for Q3 2022 was ¥0.0132, a decline of 90.14% compared to the same period last year[5] - Total operating revenue for the third quarter was ¥2,750,789,217.12, a decrease of 18.5% compared to ¥3,374,049,354.76 in the same period last year[19] - Net profit for the quarter was ¥97,283,921.32, a decline of 69.2% from ¥316,044,702.20 in the previous year[20] - Basic earnings per share decreased to ¥0.0868, down from ¥0.2570 in the same quarter last year[21] - The company reported a comprehensive income total of ¥99,645,489.82, down from ¥315,799,330.37 in the previous year[21] Cash Flow - The operating cash flow for the year-to-date period reached ¥346,455,455.66, showing a significant increase of 242.99%[10] - The net cash flow from operating activities for Q3 2022 was ¥346,455,455.66, a significant improvement compared to a negative cash flow of ¥242,301,623.97 in Q3 2021[24] - Total cash outflow from operating activities amounted to ¥2,931,988,495.68, down from ¥4,954,643,622.21 in the same period last year[24] - Cash inflow from financing activities reached ¥1,300,861,466.91, compared to ¥955,574,111.69 in Q3 2021, indicating a 36% increase[24] - The net cash flow from financing activities was ¥227,979,992.01, a substantial increase from ¥17,265,006.59 in the previous year[24] - The total cash and cash equivalents at the end of Q3 2022 stood at ¥2,062,533,053.46, up from ¥1,286,352,038.29 at the end of Q3 2021[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,297,784,554.71, reflecting a 1.79% increase from the end of the previous year[5] - Current assets total 4,098,893,620.87 RMB, compared to 3,997,328,585.49 RMB at the start of the year[16] - The company reported a total current liability of 2,014,936,448.19 RMB, compared to 1,918,649,965.75 RMB previously[16] - The total liabilities amounted to ¥2,591,617,698.51, slightly up from ¥2,562,945,067.79 in the previous year[20] - The total equity attributable to shareholders of the parent company increased to ¥4,608,622,015.72 from ¥4,498,932,071.60 year-on-year[20] Investments and Expenses - The company reported a 31.48% increase in trading financial assets, totaling ¥365,822,520.56, primarily due to an increase in short-term investments[10] - The company experienced a significant reduction in sales expenses, which amounted to ¥533,487,909.49, down 52.11% year-on-year[10] - Research and development expenses were ¥30,609,395.13, down 26.2% from ¥41,484,518.46 year-on-year[20] - Sales expenses significantly decreased to ¥533,487,909.49, down 52.2% from ¥1,113,955,831.75 in the previous year[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 60,102[12] - The largest shareholder, Changjiang Runfa Group, holds 38.08% of shares, totaling 470,667,365 shares, with 319,334,000 shares pledged[12] Other Financial Metrics - The company recorded a 1069.43% increase in credit impairment losses, totaling ¥33,161,844.09, primarily due to the consolidation of Hunan Sanqing[10] - The company received government subsidies amounting to ¥21,895,267.70, which is a 356.26% increase compared to the previous year[10] - Cash paid to employees and for employee benefits was ¥210,170,277.86, compared to ¥200,664,975.59 in the same quarter last year[24] - The impact of exchange rate changes on cash and cash equivalents was positive at ¥2,953,443.48, compared to a negative impact of ¥2,760,242.77 in the previous year[24]
长江健康(002435) - 2022 Q3 - 季度财报